Primary Aldosteronism Treatment Market: Aldosterone receptor antagonists segment is estimated to hold a leading market share

Primary aldosteronism is a hormonal disorder that leads to high blood pressure. In primary aldosteronism, high levels of aldosterone hormone are produced, causing increased levels of sodium and low levels of potassium in the body. High levels of sodium in the blood lead to high volume of blood and ultimately high blood pressure. Primary aldosteronism is caused due to a growth of a benign tumor on the adrenal cortex. The condition is known as adrenocortical adenoma or Conn’s syndrome. Aldosterone receptor antagonists drugs are used as the first line of treatment for the management of symptoms of primary aldosteronism.

Request Brochure of Report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47586

The primary aldosteronism treatment market is projected to be primarily driven by the rise in incidence rates of primary aldosterone disorder across the globe. Primary aldosterone disorders are mainly caused by Conn’s syndrome and over activity of the adrenal glands.

Easy availability and low cost of diagnostics test for primary aldosterone disorders such as oral salt loading tests, saline infusion tests, and fludrocortisone suppression tests, etc. are likely to drive the expansion of the primary aldosteronism treatment market during the forecast period. On the other hand, side effects of therapeutic drugs such as decreased sexual desire, impotence, menstrual irregularities in women, male breast enlargement, etc. are anticipated to restrain the market in the near future.

Request for Analysis of COVID-19 Impact on Primary Aldosteronism Treatment Market –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=47586

The global primary aldosteronism treatment market can be segmented based on drug class, distribution channel, and geography. In terms of drugs class, the global primary aldosteronism treatment market can be classified into aldosterone receptor antagonists and potassium sparring diuretics. Aldosterone receptor antagonists, also known as antimineralocorticoids, are a group of medicines that are used to block the effects of the aldosterone hormone produced in the adrenal gland. Aldosterone drugs stimulate/increase the sodium reabsorption activity of the kidneys, salivary glands, and sweat glands. Aldosterone receptor antagonists drugs block the reabsorption of sodium and thus decrease blood pressure. The aldosterone receptor antagonists segment is estimated to hold a leading primary aldosteronism treatment market share by the end of 2026 owing to increased usage of aldosterone drugs as the first line of treatment and easy availability and low cost of drugs. Aldolactone and CaroSpir are the most commonly used drugs for the treatment of primary aldosteronism.  In terms of distribution channel, the global primary aldosteronism treatment market can be categorized into hospital pharmacy, retail pharmacy, and online pharmacy store.

Based on geography, the global primary aldosteronism treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to hold a prominent share of the global primary aldosteronism treatment market owing to high prevalence of adrenal adenoma, a benign tumor of adrenal cortex; easy availability and low cost of drugs; and well-established health care facilities in the region. Europe is projected to constitute a key share of the global primary aldosteronism treatment market by the end of 2026. The primary aldosteronism treatment market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, owing to rapidly increasing number of patients with primary aldosterone disorder in China, India, and Japan; increasing adoption of a western life style;  changing health care infrastructure in the region; and easy availability of therapeutic drugs.

Pre Book Primary Aldosteronism Treatment Market Report at –

https://www.transparencymarketresearch.com/checkout.php?rep_id=47586&ltype=S

The global primary aldosteronism treatment market is highly fragmented, with a large number of manufactures holding a prominent share in various regions. Key players operating in the global primary aldosteronism treatment market include Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Accord Healthcare, Novartis AG, Concordia International Corp., Apotex Inc.,and  Allergan plc.,.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/

Back to news